T-cell immunotherapy
Atara Biotherapeutics Faces Clinical Hold on EBVALLO and Pipeline Candidate Due to Manufacturing Site Inspection Issues
Atara Biotherapeutics, EBVALLO, Clinical Hold, FDA, Manufacturing Site Inspection, Cell Therapy, T-Cell Immunotherapy
FDA Rejects Atara’s Ebvallo Due to Manufacturing Issues, Not Efficacy or Safety Concerns
Atara Therapeutics, Ebvallo, FDA rejection, manufacturing issues, post-transplant lymphoproliferative disease (PTLD), Epstein-Barr virus (EBV), T-cell immunotherapy, Pierre Fabre Laboratories.